Clinical Study on Baiji Decoction in the Treatment of Pulmonary Tuberculosis of Qi-Yin Deficiency Syndrome
Objective:To investigate the clinical efficacy of Baiji decoction in the treatment of pulmonary tuberculosis of qi-yin deficiency syndrome.Methods:A total of 74 patients with pulmonary tuberculosis of qi-yin deficiency syndrome treated in a hospital from May 2021 to October 2023 were selected and assigned to the control group and observation group by random number table method,with 37 patients in each group.The control group was treated with conventional western medicine,and the observation group was treated with Baiji decoction in addition to the treatment given in the control group.The two groups were treated for 6 months.The traditional Chinese medicine(TCM)syndrome score,inflammatory index[erythrocyte sedimentation rate(ESR),osteopontin(OPN)],microbiological negativity conversion,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the TCM syndrome scores,ESR and OPN levels were decreased in the two groups,with the observation group showing lower scores than the control group(P<0.05).The microbiological negativity conversion rate in the observation group(89.19% )was higher than that in the control group(70.27%,χ2=4.097,P=0.043).The total response rate in the observation group(91.89% )was higher than that in the control group(72.97%,P<0.05).During the treatment period,there was no statistically significant difference in the incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Baiji decoction shows better clinical efficacy in the treatment of pulmonary tuberculosis of qi-yin deficiency syndrome,improving the microbiological negativity conversion rate,reducing inflammatory response,without increasing the risk of adverse reactions.
万方数据
维普
